Pharmaceuticals
Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B
-- Estimated 1.59 million chronic hepatitis B (CHB) patients in the U.S. -- Interim results of the Phase IIb trial conducted on CHB patients in China showed that in patients with the baseline hepatitis B surface antigen (HBsAg) level ≤ 500 IU/mL, approximately 19% (3/16) of patients in the treatm...
The Philippines Has Approved ReCOV For Phase II/III Cinical Trial
* Recombinant Two-Component COVID-19 Vaccine (ReCOV) was approved for International Phase II/III Clinical Trial * ReCOV induced high levels of neutralizing antibodies against SARS-CoV-2 and Variants of Concern such as Omicron and Delta * Rhecogen , a subsidiary focused on mRNA vaccines of th...
CStone announces the clinical data from registrational study of Sugemalimab in stage III non-small cell lung cancer published in The Lancet Oncology
SUZHOU, China, Jan. 15, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the registrational clinical...
CStone announces the registrational clinical study results of sugemalimab in stage IV non-small cell lung cancer published in The Lancet Oncology
SUZHOU, China, Jan. 15, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that results of the GEMSTONE-302...
French Consul General in Guangzhou led a delegation to visit Biosyngen in China-Singapore Guangzhou Knowledge City
GUANGZHOU, ChinaJan. 15, 2022 /PRNewswire/ -- On the afternoon of January 14th, Mr. Sylvain FOURRIERE, Consul General ofFrance in Guangzhou, and officers from consulates general of 9 countries includingBritain, Canada and Switzerland visited China-Singapore Guangzhou Knowledge City andSingapore -...
LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant
Results from ongoing testing and monitoring of COVID-19 variants shows the rapid microfluidic test detects Omicron at a comparable sensitivity to other variants LONDON, Jan. 14, 2022 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced tha...
Everest Medicines Enters into a Global Licensing Agreement to Develop and Commercialize Singapore's Experimental Drug Development Centre's 3CL Protease Inhibitors as Potentially Best-in-Class COVID-19 Oral Antiviral Treatments Worldwide
SHANGHAI, Jan. 14, 2022 /PRNewswire/ -- Everest Medicines
Accuredit Therapeutics and N1 Life Form a Joint Venture Named 'Napoltec', Dedicated to the Development of Therapeutic Drug Delivery Systems and Pressing Ahead Clinical Translation
SUZHOU, China, Jan. 13, 2022 /PRNewswire/ -- Accuredit Therapeutics (Suzhou) Co., Ltd. (hereinafter referred to as Accuredit), an emerging company based on new generations of safe and highly targeted gene editing therapies, and N1 Life, a biotech company focused on developing cutting-edge drug de...
NeuroAiD(TM)II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression
SINGAPORE, Jan. 13, 2022 /PRNewswire/ -- Moleac is pleased to announce the release of the ATHENE study results, published in the Journal of the American Medical Director Association (JAMDA)1. Alzheimer's Disease (AD) and other dementias cause a heavy economic and public healthcare burden worldw...
Enrollment Completed in Phase II Clinical Study of KN026 Combined with KN046
* Interim analysis expected in the second quarter of 2022 SUZHOU, China, Jan. 13, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical study of KN026 (HER2 bispecific antibody) combined with KN046 (PD-L1/CTLA-4 bispecific antibody) (KN026-203) has su...
CStone announces phase 2 GEMSTONE-201 trial met primary endpoint of objective response rate (ORR) in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL)
* Sugemalimab has the potential to become the world's first immunotherapy to be approved for patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) * The National Medical Products Administration (NMPA) of China has granted the Breakthrough Therapy Designati...
Seegene Unveils Blueprint for the Future of Molecular Diagnostics, Including Open Development Platform at the 40th Annual J.P. Morgan Healthcare Conference
SEOUL, South Korea, Jan. 13, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics (MDx) company, today, unveiled its blueprint for the future during a presentation at the 40th annual J.P. Morgan Healthcare virtual Conference. Dr.Jong-Yoon Chun, CEO of Seegene...
South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine
GAITHERSBURG, Md., Jan. 12, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited, a vaccine business subsidiary of Korea-based SK Group, today...
PostEra Closes $24M in New Financing to Advance Drug Discovery
BOSTON, Jan. 11, 2022 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced $24M in equity financing to accelerate medicinal chemistry and bring new cures to patients. PostEra will use the proceeds to advance a series of ...
Cambrex Celebrates its 40th Anniversary while Investing over $100 million in New Drug Substance Manufacturing Capacity
EAST RUTHERFORD, N.J., Jan. 11, 2022 /PRNewswire/ -- Cambrex recently celebrated the 40th anniversary of its founding in 1981. Following forty years of growth and transformation into a leading global contract development and manufacturing organization (CDMO), Cambrex continues its commitment to ...
Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets
SHANGHAI and NEW YORK, Jan. 11, 2022 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading innovation-driven international healthcare group inChina and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)...
Latest Study Shows Encouraging Results of CanSinoBIO's Inhaled COVID-19 Vaccine as Heterologous Booster
TIANJIN, China, Jan. 11, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced thatPreprints with The Lancet, a collaboration between the research sharing platform SSRN and The Lancet, published a clinical study on the safety and immunogenicity of ...
SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections
COPENHAGEN, Denmark, Jan. 11, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is pleased to announce that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) Application, for our first development candidate, enabli...
Pfizer Drives Cultural Change in Sustainable and Accessible Data with MicroStrategy
SINGAPORE, Jan. 11, 2022 /PRNewswire/ -- MicroStrategy
Keep Your Home Safe and Build a Protected Community Against Omicron with Circle HealthPod
* Circle HealthPod detects >99.9% of known COVID-19 strains, including the Omicron variant, in approximately 20 minutes * With technology developed at the University of Oxford, the Circle HealthPod is a CE-IVD marked rapid detection system with 98.4% molecular accuracy * Frequent testing wit...
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 286 media titles]
2024-04-19 13:25Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 275 media titles]
2024-04-23 15:43INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 272 media titles]
2024-04-24 17:09